| Literature DB >> 31867512 |
Sandeep V H S Bhaskaruni1, Suresh Maddila1, Werner E van Zyl1, Sreekantha B Jonnalagadda1.
Abstract
class="Chemical">Nickel oxide loaded onEntities:
Year: 2019 PMID: 31867512 PMCID: PMC6921676 DOI: 10.1021/acsomega.9b02608
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Structures of commercially available 1,4-dihydropyridine drugs.
Figure 2Powder X-ray diffractogram of 2.5% NiO–ZrO2 catalyst.
Figure 3TEM micrograph of 2.5% NiO–ZrO2 catalyst.
Figure 4(a) SEM micrograph, (b) mapping, and (c) EDS spectra of 2.5% NiO/ZrO2 catalyst.
Figure 5N2 adsorption–desorption isotherms of 2.5% NiO/ZrO2 catalyst.
Figure 6Pyridine FT-IR spectra of 2.5% NiO/ZrO2 catalyst. L = Lewis acidic sites; B + L = Brønsted and Lewis acidic sites; B = Brønsted acidic sites.
Scheme 1Optimization Reaction Conditions for 5a Synthesis
Effect of Different Catalysts on the Synthesis of 5aa
| entry | catalyst | solvent | condition | time (h) | yield
(%) |
|---|---|---|---|---|---|
| 1 | – | – | RT | 8 | 12 |
| 2 | – | – | reflux | 8 | 17 |
| 3 | TEA | EtOH | RT | 5.0 | 30 |
| 4 | pyridine | EtOH | RT | 7.0 | 27 |
| 5 | DABCO | EtOH | RT | 5.0 | 25 |
| 6 | NaOH | EtOH | RT | 6.0 | 33 |
| 7 | K2CO3 | EtOH | RT | 6.0 | 29 |
| 8 | AcOH | EtOH | RT | 5.5 | 36 |
| 9 | FeCl3 | EtOH | RT | 5.0 | 38 |
| 10 | PTSA | EtOH | RT | 6.0 | 45 |
| 11 | TFA | EtOH | RT | 4.0 | 40 |
| 12 | SiO2 | EtOH | RT | 4.0 | 53 |
| 13 | ZrO2 | EtOH | RT | 2.0 | 68 |
| 14 | Al2O3 | EtOH | RT | 3.5 | 60 |
| 15 | NiO | EtOH | RT | 2.5 | 65 |
| 16 | 2.5% CuO/ZrO2 | EtOH | RT | 1.0 | 73 |
| 17 | 2.5% CeO2/ZrO2 | EtOH | RT | 0.75 | 81 |
| 18 | 2.5% NiO/ZrO2 | EtOH | RT | 0.33 | 98 |
| 19 | 1% NiO/ZrO2 | EtOH | RT | 0.50 | 91 |
| 20 | 5% NiO/ZrO2 | EtOH | RT | 0.41 | 94 |
Reaction conditions: 2,3,4-trimethoxybenzaldehyde (1 mmol) (1), ethyl acetoacetate (1 mmol) (2), 1,3-cyclohexadione (1 mmol) (3), and ammonium acetate (1 mmol) (4); 5 mL of solvent; and stirring at RT.
Isolated yields.
100 mg of catalyst.
60 mg of catalyst.
30 mg of catalyst.
No catalyst.
Role of Different Solvent in the Synthesis of 5aa
| entry | solvent | time (h) | yield (%) |
|---|---|---|---|
| 1 | 4.0 | – | |
| 2 | toluene | 4.0 | – |
| 3 | DMF | 1.3 | 19 |
| 4 | THF | 1.1 | 24 |
| 5 | MeCN | 1.0 | 31 |
| 6 | CH3OH | 0.75 | 76 |
| 7 | C2H5OH | 0.33 | 98 |
Reaction conditions: 2,3,4-trimethoxybenzaldehyde (1 mmol) (1), ethyl acetoacetate (1 mmol) (2), 1,3-cyclohexanedione (1 mmol) (3), and ammonium acetate (1 mmol) (4); 5 mL of solvent; and stirring at RT.
DMF, dimethyl formamide; THF, tetrahydrofuran; MeCN, acetonitrile; CH3OH, methanol; C2H5OH, ethanol.
No product.
Optimization of the Amount of 2.5% NiO/ZrO2 Catalyst for the Synthesis of 5aa
| entry | catalyst (mg) | time (h) | yield (%) |
|---|---|---|---|
| 1 | 10 | 0.83 | 74 |
| 2 | 20 | 0.5 | 85 |
| 3 | 30 | 0.33 | 98 |
| 4 | 40 | 0.33 | 98 |
| 5 | 50 | 0.33 | 97 |
| 6 | 60 | 0.33 | 97 |
Reaction conditions: 2,3,4-trimethoxybenzaldehyde (1 mmol) (1), ethyl acetoacetate (1 mmol) (2), 1,3-cyclohexadione (1 mmol) (3), and ammonium acetate (1 mmol) (4); 5 mL of EtOH; and stirring at RT.
Figure 7Library synthesis of novel unsymmetrical 1,4-dihydropyridine derivatives. Reaction conditions: substituted aldehydes (1 mmol) (1), ethyl acetoacetate (1 mmol) (2), 1,3-cyclohexadione/5,5-dimethyl-1,3-cyclohexanedione (1 mmol) (3), and ammonium acetate (1 mmol) (4); 5 mL of ethanol; 2.5% NiO/ZrO2 (30 mg) catalyst; and stirring at RT; melting point (m.p.) in °C.
Figure 8Single-crystal X-ray structure of 5a.
Figure 9Single-crystal X-ray structure of 5c.
Single-Crystal Data of 5a and 5c
| identification code | ||
| empirical formula | C22H27NO6 | C20H23NO3 |
| formula weight | 401.44 | 325.39 |
| temperature (K) | 100.0 | 100.0 |
| crystal system | orthorhombic | triclinic |
| space group | Pna21 | P-1 |
| a (Å) | 14.6836(6) | 7.29920(10) |
| b (Å) | 8.4477(3) | 9.58180(10) |
| c (Å) | 15.5290(6) | 12.3976(2) |
| α (°) | 90 | 83.9450(10) |
| β (°) | 90 | 86.8650(10) |
| γ (°) | 90 | 71.9730(10) |
| volume (Å3) | 1926.26(13) | 819.69(2) |
| Z | 4 | 2 |
| ρcalc (g/cm3) | 1.384 | 1.318 |
| μ (mm–1) | 0.101 | 0.088 |
| F(000) | 856.0 | 348.0 |
| crystal size (mm3) | 0.38 × 0.24 × 0.16 | 0.31 × 0.23 × 0.12 |
| radiation | Mo Kα (λ = 0.71073) | Mo Kα (λ = 0.71073) |
| 2Θ range for data collection (°) | 5.246–56.7 | 3.304–57.038 |
| index ranges | –19 ≤ h ≤ 15, −11 ≤ k ≤ 11, −20 ≤ l ≤ 20 | –9 ≤ h ≤ 9, −12 ≤ k ≤ 12, −16 ≤ l ≤ 16 |
| reflections collected | 13 133 | 26 777 |
| independent reflections | 4622 [ | 4083 [ |
| data/restraints/parameters | 4622/1/267 | 4083/0/220 |
| goodness-of-fit on | 1.024 | 1.048 |
| final | ||
| final | ||
| largest diff. peak/hole (e Å–3) | 0.29/–0.21 | 0.40/–0.19 |
Figure 1013C chemical shifts and selected HMBC interactions of −CH and −NH protons of 5a.
Figure 11LC–MS spectra of the reaction mixture with compound 5a.
Scheme 2Formation of Unsymmetrical 1,4-DHPs 5a in the Presence of NiO/ZrO2 Catalyst
Comparison of Present Work with Previous Reports
| catalystref | solvent | reaction condition | time | yield (%) |
|---|---|---|---|---|
| sulfamic
acid[ | MeOH | reflux | 24 h | 47–92 |
| γ-Fe2O3/Cu@cellulose[ | solvent-free | RT | 9–30 min | 80–98 |
| SBA-15@AMPD-Co[ | solvent-free | 100 °C | 35–90 min | 90–97 |
| Fe3O4@D-NH-(CH2)4-SO3H[ | EtOH | reflux | 40 min | 86–90 |
| Cu-Adenine@boehmite[ | EtOH | reflux | 20–120 min | 89–97 |
| nano-tungsten trioxide-supported sulfonic
acid (n-WSA)[ | solvent-free | 100 °C | 10–25 min | 86–98 |
| sulfated boric acid nanoparticles[ | EtOH | 60 °C | 20–60 min | 86–98 |
| chitosan-supported copper(II) sulfate (CSCS)[ | EtOH | reflux | 20–87 min | 80–97 |
| Fe3O4@SiO2@Si-(CH2)3@melamine-picolineimine@SO3H[ | solvent-free | 60 °C | 4–11 min | 48–90 |
| sulfated polyborate[ | solvent-free | 90 °C | 15–35 min | 85–95 |
| Fe3O4/KCC-1/BPAT[ | water | reflux | 4 h | 79–88 |
| chitosan-supported vanadium oxo[ | solvent-free | 85 °C | 20–55 min | 81–94 |
| magnetic guanidinylated chitosan[ | EtOH | reflux | 15 min | 82–89 |
| nano-ZrO2-SO3H (n-ZrSA)[ | solvent-free | 80 °C | 35–65 min | 84–93 |
| Gd(OTf)3[ | EtOH | RT | 5–6 h | 82–89 |
| nicotinic acid[ | solvent-free | 80 °C | 2–7 min | 87–96 |
| hydromagnesite[ | water | 90 °C | 20–45 min | 80–98 |
| Cu(OTf)2[ | EtOH | 100 °C | 15 min | 81–98 |
| ascorbic acid[ | solvent-free | 80 °C | 1.5–4.5 h | 70–96 |
| NS-C4(DABCO-SO3H)2·4Cl[ | solvent-free | 100 °C | 8–50 min | 80–100 |
| CBr4[ | EtOH | RT | 3–6 h | 70–98 |
| aminated CNTs[ | EtOH | reflux | 3–6 h | 80–96 |
| 2.5% NiO/ZrO2 (present work) | EtOH | RT | 20–45 min |
Figure 12Recycling study of 2.5% NiO/ZrO2 catalyst for the synthesis of 1,4-dihydropyridine 5a.
Figure 13Hot filtration test results of 2.5% NiO/ZrO2 catalyst for 5a. Reaction conditions: 2,3,4-trimethoxybenzaldehyde (1 mmol) (1), ethyl acetoacetate (1 mmol) (2), 1,3-cyclohexadione (1 mmol) (3), and ammonium acetate (1 mmol) (4); 5 mL of EtOH; and stirring at RT.
Scheme 3Synthesis of Novel 1,4-Dihydropyridines